Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 15;9(3):4239-4248.
doi: 10.18632/oncotarget.23279. eCollection 2018 Jan 9.

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis

Guanghong Huang  1 , Xin Sun  1 , Dapeng Liu  1 , Yunfeng Zhang  1 , Boxiang Zhang  1 , Guodong Xiao  1 , Xiang Li  1 , Xiao Gao  1 , Chenhao Hu  1 , Meng Wang  1 , Hong Ren  1 , Sida Qin  1
Affiliations

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis

Guanghong Huang et al. Oncotarget. .

Abstract

Antibodies against the immune checkpoint proteins PD-1 and PD-L1 are novel therapeutic drugs for the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials involving these drugs achieved breakthroughs in patients previously treated for advanced NSCLC. However, the results of these clinical studies are not consistent. In this report, we performed a meta-analysis to assess the efficacy and safety of anti-PD-1/PD-L1 antibodies compared with docetaxel treatment for advanced NSCLC patients from 5 randomized clinical trials. We demonstrated that the patients in anti-PD-1/PD-L1 antibody therapy groups had significantly longer overall survival (OS) (HR = 0.69, 95% CI 0.63-0.75, P < 0.05) and progression-free survival (PFS) (HR = 0.76, 95% CI 0.63-0.92, P < 0.05) than those in chemotherapy groups, especially PD-L1 positive patients. Anti-PD-1/PD-L1 antibodies improved the objective response rate (ORR) compared with docetaxel (OR = 1.64, 95% CI 1.19-2.26, p < 0.05). In addition, the anti-PD-1/PD-L1 antibody therapy had fewer treatment-related adverse events (AEs) (OR = 0.33, 95% CI 0.28-0.39, P < 0.05) than docetaxel, especially the grade ≥3 AEs (OR = 0.18, 95% CI 0.12-0.28, P < 0.001). In conclusion, our study revealed that, compared with docetaxel, anti-PD-1/PD-L1 antibody therapy improved clinical efficacy and safety in previously treated advanced NSCLC patients. This therapy may be a promising treatment for advanced NSCLC patients.

Keywords: Immune checkpoint inhibitor; NSCLC; PD-1/PD-L1; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart of selecting relevant studies
Figure 2
Figure 2. The forest plot of the overall survival (OS) in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel
(A) total; (B) subgroup analysis of OS based on PD-L1 expression level.
Figure 3
Figure 3. The forest plot of the progression-free survival (PFS) in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel
(A) total; (B) subgroup analysis of PFS based on PD-L1 expression level.
Figure 4
Figure 4. The forest plot of the objective response rate (ORR) in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel
Figure 5
Figure 5. The forest plot of the adverse events (AEs) in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel
(A) treatment-related AEs; (B) severe treatment-related AEs (Grade ≥ 3).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67:7–30. - PubMed
    1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311. - PubMed
    1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–1740. - PubMed